| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
IGH gene rearrangement (14q32.3) by FISH : 1001104
MessagePlease provide most recent Pathology report.
Test Code
MDFCPCIGH14Q or 1001104
Alias/See Also
14q34; IGH breakapart; IGH
CPT Codes
88271x2, 88275
Instructions
Bone Marrow aspirate in a green top sodium heparin tube (2-3 mL) or Peripheral Blood in a green top sodium heparin tube (2-10 mL). Tissue also accepted.
Transport Container
Blood or Bone Marrow: Do not centrifuge. Paraffin embedded formalin fixed tissue that has been fixed in 10% neutral buffered formalin for at least 6 hours and no longer than 48 hours. Two unstained slides, with tissue of 4 microns in thickness are needed for processing, accompanied by a circled H & E clearly indicating the area to be examined.
Transport Temperature
Blood or Bone Marrow: Ambient temperature within 24 hours. Specimen can be refrigerated if not transported immediately. Do not freeze. Protect from heat with a cold pack. Paraffin embedded tissue block: Ambient or on ice pack in summer. Slides: Ambient.
Specimen Stability
Blood and Bone Marrow: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: Unacceptable
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Paraffin embedded tissue: Ambient: Indefinitely; Refrigerated: Indefinitely; Frozen: Unacceptable
Methodology
Fluorescence in situ hybridization (FISH)
Setup Schedule
Monday - Friday
Report Available
Up to 7 days
Limitations
Laboratory test results should always be considered in the context of clinical observations. This test was developed and its performance characteristics determined by med fusion. It has not been cleared or approved by the U.S. Food and Drug Administration
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
(FDA). The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational for research. This laboratory is certified under the Clinical Laboratory Improvement Amendments
of 1988 (CLIA) as qualified to perform high complexity clinical laboratory testing.
Reference Range
An interpretive report will be provided.
Clinical Significance
The IGH gene rearrangement is thought to be one of the most frequent chromosome rearrangements in B-cell CLL observed by FISH. It may indicate the presence of the 14;18 or 14;19 or 11;14 translocation. About 65% of MM patients have rearrangements of the IGH gene on chromosome 14q32. Multiple partners for the 14q32 chromosome translocation in MM patients have been detected. The most common IGH rearrangement in MM, seen in ~15-20% of patients, is the t(11;14)(q13q32) translocation. MM with t(11;14) is associated with CD20 expression, lymphoplasmacytic morphology, hyposecretory disease, and lambda light chain usage. The literature suggests that the t(11;14) rearrangement and the related t(6;14)(p21;q32) translocation confer a favorable or neutral outcome in MM patients. The t(4;14)(p16.3;q32), seen in about 15% of patients, is associated with a poor prognosis, aggressive disease, and a shortened survival. The t(14;16)(q32;q23), seen in about 5% of patients, confers a very poor prognosis. Both the t(4;14) and the t(14;16) appear to have a poor prognosis regardless of treatment modality and usually are only detectable by FISH (and not classical cytogenetic analysis).
Performing Laboratory
med fusion
